Blastomycosis elicits a pyogranulomatous inflammatory response that involves a prominent recruitment of neutrophils to the site of infection. Although neutrophils are efficiently recruited to the site of infection, this event is paradoxically coupled with the host's inability to control infection by Blastomyces dermatitidis, the causative agent. The mechanisms underlying this characteristic pyogranulomatous response and inability of neutrophils to kill the yeast are poorly understood. We recently reported that the fungal protease dipeptidyl peptidase IVA (DppIVA) promotes B. dermatitidis virulence by cleaving a dipeptide from the N-terminus of C-C chemokines and granulocyte/macrophage-colony stimulating factor, thereby inactivating them.
| INTRODUCTION
Polymorphonuclear neutrophils (PMNs), or neutrophils, are central to the host immune response because conditions in which they are either reduced (neutropenia) or functionally impaired (e.g., chronic granulomatous disease) increase the risk of acquiring bacterial and fungal infections (Babior, 1999; Geiszt, Kapus, & Ligeti, 2001; Zeidler, Germeshausen, Klein, & Welte, 2009 ). Neutrophils, once present at the site of infection, utilize a plethora of antimicrobial activities to kill invading microorganisms. These activities include phagocytosis of pathogens, production of toxic reactive oxygen species (ROS), initiation of the myeloperoxidase-hydrogen peroxide (H 2 O 2 ) halide system, release of several types of granules that contain antimicrobial proteins and enzymes, and formation of neutrophil extracellular traps that entangle and kill extracellular pathogens (Brinkmann et al., 2004; Klebanoff, 1967 Klebanoff, , 1968 Kolaczkowska & Kubes, 2013; Laible & Germaine, 1985; Reeves et al., 2002) . Therefore, in order for a pathogen to establish infection, it must withstand or sabotage the neutrophil antimicrobial response.
Blastomyces dermatitidis is one such pathogen, as evidenced by the fact that neutrophils, in the absence of serum, inefficiently kill the yeast (Brummer & Stevens, 1982 Drutz & Frey, 1985; Sixbey, Fields, Sun, Clark, & Nolan, 1979) . Diminished killing in the absence of serum indicates a role for complement. This impairment also may be due to the large size of B. dermatitidis yeast because smaller, phagocytosable yeast such as Candida albicans demonstrate efficient fungal uptake and killing (Kurita et al., 1991) . A single B. dermatitidis yeast is about 8-10 μM, which rivals the size of human neutrophils (Drutz & Frey, 1985) . Neutrophils are unable to fully phagocytose this yeast, which spares the fungus from the concentrated acidic and degradative environment of phagolysosomes (Flannagan, Cosio, & Grinstein, 2009) . The activation of neutrophils may also be impaired via protease virulence factors of B. dermatitidis. The fungus releases an extracellular protease dipeptidyl peptidase IVA (DppIVA) that cleaves and inactivates granulocyte/macrophage-colony stimulating factor (GM-CSF), which is a potent activator of neutrophils, thereby rendering cleaved GM-CSF an antagonist for its receptor (Broxmeyer et al., 2012) . This DppIVA action prevents neutrophil priming via GM-CSF and further reduces the fungicidal capacity of neutrophils (Sterkel et al., 2016) . Mammalian DppIV cleaves a large number of substrates including many chemokines and cytokines (Ou, O'Leary, & Broxmeyer, 2013) . Blastomyces DppIVA may likewise act on its predicted cleavage site within additional substrates, including the immunologically active host targets of mammalian DppIV. DppIVA may thus thwart neutrophil function and promote disease pathogenesis in further ways that have not been studied, for example, by altering the activity of ELR + CXC chemokines.
The CXC family of chemokines can be divided into two groups,
ELR
− chemokines and ELR + chemokines. The ELR + chemokines possess an ELR motif (glutamate, leucine, and arginine) N-terminally adjacent to the first cysteine of the CXC motif, and this group of chemokines has been shown to modulate neutrophil activity. The seven members of the human ELR + CXC family (CXCL-1, -2, -3, -5, -6, -7, and -8) differ in the extent to which they modulate neutrophil activity (Ahuja & Murphy, 1996; Clark-Lewis, Schumacher, Baggiolini, & Moser, 1991; Geiser, Dewald, Ehrengruber, Clark-Lewis, & Baggiolini, 1993; Magazin et al., 1992; Proost et al., 1998; Wuyts et al., 1999) .
Once produced, these chemokines are subject to posttranslational modifications, such as discrete N-terminal truncations that can enhance their activity relative to their intact counterparts (Ahuja & Murphy, 1996; Clark-Lewis et al., 1991; Geiser et al., 1993; King et al., 2000; Proost et al., 1998; Wuyts et al., 1999) . In general, the larger the N-terminal truncation, the more potent the chemokine becomes as long as the ELR-motif is undisturbed. For instance, human (h) CXCL-8 is secreted as a 77 amino acid protein, but naturally occurring forms where 5, 6, or 7 amino acids are removed from the N-terminus have been identified. These N-terminally truncated forms of hCXCL-8 promote neutrophil migration and elastase release to a greater extent than intact hCXCL-8 (Clark- Lewis et al., 1991) . Similar trends have been observed for some N-terminally truncated forms of hCXCL-1, -2, -3, and -5, which induce greater calcium flux and are more chemotactic for neutrophils than their full-length forms (King et al., 2000; Wuyts et al., 1999) . For example, a 4 amino acid Nterminal truncated form of hCXCL-2 induces neutrophil ROS production to a greater extent than does the full-length protein (King et al., 2000) .
Although the enhancement of ELR + CXC chemokine function through N-terminal cleavage is the general trend, it is not the absolute rule. For instance, an N-terminally dipeptide truncated form of CXCL-6 fails to enhance neutrophil migration relative to the intact protein (Proost et al., 1998 To monitor cleavage, we incubated each chemokine in the presence or absence of rDppIVA and analyzed the products by mass spectrometry. We found a reduction in mass of mCXCL-1 and hCXCL-2 after rDppIVA treatment that is equivalent to the loss of their respec- 
The family of ELR + CXC chemokines that modulate neutrophil function are listed along with the first five N-terminal amino acids of the human or murine biologically relevant form (Bachelerie et al., 2014; Zlotnik & Yoshie, 2012) . The two N-terminal residues of the ELR + CXC chemokines that are potential DppIV substrates are underlined and in bold; canonical penultimate proline or alanine residues are in red and noncanonical penultimate serine residues are in black. Human CXCL-1, CXCL-2, CXCL-3, and CXCL-6 share synteny with murine CXCL-3, CXCL-2, CXCL-1, and CXCL-5, respectively (Bachelerie et al., 2014 2.2 | mCXCL-1(2-72) and hCXCL-2(3-73) are more potent than intact mCXCL-1 and hCXCL-2 in chemoattraction of neutrophils
We previously characterized the effects of DppIVA sufficient and deficient B. dermatitidis (by RNA interference) in vivo, revealing that DppIVA plays and important role in virulence (Sterkel et al., 2016) .
Neutrophils are recruited to tissues infected with B. dermatitidis (Littman, Wicker, & Warren, 1948) , and many ELR + CXC chemokines are known to have enhanced chemotactic activity with small, discrete N-terminal truncations (Clark-Lewis et al., 1991; Wuyts et al., 1999) .
Because murine CXCL-1 can rapidly recruit neutrophils to the lung when given intratracheally (it) to mice with fungal infection (Jhingran et al., 2015) , we delivered intact (1-72) or cleaved (3-72) mCXCL-1 intratracheally to mice along with heat inactivated B. dermatitidis yeast.
Five hours after intratracheal administration, heat-killed yeast alone increased the number of neutrophils that accumulated in the lung capillaries (Figure 2b,c) . However, the proportion of neutrophils that had extravasated across the capillaries, as measured by staining with an intravenously injected antibody (Anderson et al., 2014) , was not significantly increased by mCXCL-1(3-72), (Figure 2d) . Thus, the effect of DppIVA trimming on mCXCL-1 appears to be on neutrophil slowing and adhesion along the endothelium.
The ELR + CXC family of chemokines is divergent across species.
Murine CXCL-1 shares closest homology with human CXCL-3 that is not cleaved by rDppIVA (Table 1; Nomiyama, Osada, & Yoshie, 2010; Zlotnik & Yoshie, 2012) . To understand how cleavage of ELR + CXC chemokines may impact the neutrophil response during blastomycosis in humans, we focused on human CXCL-2 because it is cleaved by rDppIVA. We postulated that rDppIVA cleavage of hCXCL-2 would enhance the chemokine's ability to induce human The migration results over a range of chemokine concentrations were averaged for 3 to 6 donors tested at a given condition, and the mean and SEM for each condition is displayed. A paired t test was used to determine the statistical significance of differences at each chemokine concentration for neutrophil migration in response to hCXCL-2 versus hCXCL-2(3-73). *p < .05; **** p < .0001
2.3 | Cleaved hCXCL-2(3-73) primes ROS production less efficiently than intact hCXCL-2
A central effector function of neutrophils is their production of ROS (Klebanoff, 1967 (Klebanoff, , 1968 (Guichard et al., 2005; Sengelov et al., 1995) . Binding of ELR + CXC chemokines to their receptors on neutrophils can induce a slight respiratory burst in neutrophils, as has been observed for hCXCL-8 and hCXCL-2 (Magazin et al., 1992; Yuo et al., 1991) . Minor N-terminal truncations of ELR + CXC chemokines, such as the deletion of four amino acids from the NH 2 -terminus of hCXCL-2, can enhance its ability to induce the neutrophil oxidative burst (King et al., 2000) . In addition, ELR + CXC chemokines can "prime" the oxidative burst in neutrophils, so that, upon neutrophil recognition of a secondary stimulus, primed neutrophils produce a more robust ROS response than unprimed neutrophils.
For example, hCXCL-8 primed neutrophils exposed to the secondary stimulus formylated-methionine-leucine-proline (fMLP) show much greater ROS production than unprimed neutrophils exposed to fMLP (Guichard et al., 2005) . Also, hCXCL-8 primed neutrophils produced the greatest ROS response, which was expected because hCXCL-8 is one of the most potent human ELR + CXC chemokine stimulators of neutrophil function (Geiser et al., 1993; Magazin et al., 1992) . However, to our surprise, hCXCL-2 primed neutrophils produced significantly more ROS in response to fMLP than did hCXCL-2(3-73) primed neutrophils ( Figure 3a ). In fact, cleaved, hCXCL-2(3-73)-primed neutrophils produced as little ROS as did unprimed neutrophils in response to fMLP stimulation. This result contrasts with prior studies in which more extensive N-terminal truncations of hCXCL-2 showed greater activity upon cleavage (King et al., 2000) . To our knowledge, this is the first instance where an N-terminally truncated form of an ELR + CXC chemokine still possessing its ELR-motif is actually reduced in its capacity to prime neutrophil function relative to the intact chemokine.
Although the results from the cytochrome c reduction assay are suggestive, this assay is relatively insensitive. To validate and refine our findings, we measured extracellular ROS production more accurately by its ability to cause isoluminol luminescence in a peroxidase- 2.4 | hCXCL-2 and hCXCL-2(3-73) induce degranulation to similar extents Neutrophils are armed with membrane-bound compartments chocked full of receptors, adhesins, antimicrobial proteins, and degradative enzymes (Faurschou & Borregaard, 2003; Sengelov et al., 1995) .
Secretory vesicles and granules are released extracellularly in a specified order; vesicles are most readily mobilized, followed by gelatinase granules, specific granules, and azurophilic granules (Sengelov et al., 1995) . Flavocytochrome b 558 is present in the membranes of specific granules and, upon their degranulation, is incorporated into the plasma membrane (Borregaard, Heiple, Simons, & Clark, 1983; Jesaitis et al., 1990) . Because hCXCL-2 (3-73) is impaired relative to hCXCL-2 in the ability to prime ROS production of neutrophils, we hypothesized that neutrophils primed with hCXCL-2(3-73) may likewise be impaired in degranulation.
Because secretory vesicles are the first to degranulate, we investigated whether neutrophils primed with hCXCL-2 (3-73) as opposed to intact hCXCL-2 were relatively impaired in the ability to release secretory vesicles in response to fMLP. We monitored neutrophil cell surface expression of CD35 (complement 1 receptor), which accumulates on the plasma membrane as secretory vesicles degranulate Although the sum of degranulation of specific and gelatinase granules was similar between hCXCL-2 and hCXCL-2(3-73) primed neutrophils, we could not discern if one was released to a greater extent than the other because CD66b is present on the surface of both granule types. Gelatinase granules contain a substantial amount of gelatinase B, or matrix metalloproteinase-9 (MMP-9), which can degrade several 
dermatitidis in vitro and in vivo
We previously reported that fungal DppIVA blunts antifungal immunity by targeting GM-CSF and CCR2 ligands (Sterkel et al., 2016) .
Cleavage of ELR + CXC chemokines may play an additional role in modulating neutrophil immunity. We investigated the effects of mCXCL-1 and mCXCL-1(3-72) on murine neutrophils exposed to B. dermatitidis.
To assay the effect of intact and cleaved mCXCL-1 on neutrophil killing of B. dermatitidis, we incubated murine neutrophils in vitro with DppIVA deficient yeast (Sterkel et al., 2016) in the presence of mCXCL-1 or mCXCL-1(3-72). Murine CXCL-1 modestly enhanced neutrophil killing of B. dermatitidis yeast, but rDppIVA cleavage of mCXCL-1 did not further augment neutrophil killing (Figure 6a ).
We further investigated the effects of mCXCL-1 and mCXCL-1(3-72) on neutrophil functions in vivo during early murine pulmonary blastomycosis. Two days after infection with DppIVA-deficient B. dermatitidis, we delivered mCXCL-1 or mCXCL-1(3-72)
intratracheally and investigated the effects on fungal burden and neutrophil ROS production. In vivo, the effect of mCXCL-1 mirrored neutrophil killing of yeast in vitro, where mCXCL-1 treatment reduced the fungal burden, albeit insignificantly, and treatment with mCXCL-1 (3-72) did not differ compared to intact mCXCL-1 (Figure 6b ). We used ex vivo accumulation of dihydrorhodamine-123 (DHR-123) to track ROS production in lung neutrophils (Sterkel et al., 2016) . Treatment 
| DISCUSSION
Overall, we demonstrate here that the ELR + CXC chemokines, mCXCL-1 and hCXCL-2, are substrates of the B. dermatitidis virulence factor
DppIVA. DppIVA cleaves a dipeptide from the N-terminus of mCXCL-1 and hCXCL-2 to form mCXCL-1 (3-72) and hCXCL-2(3-73).
This cleavage event is biologically significant because mCXCL-1 (3-72) and hCXCL-2(3-73) modulate neutrophil function differently than do the intact chemokines. Like several other N-terminally truncated forms of ELR + CXC chemokines, mCXCL-1(3-72) and hCXCL-2(3-73) are more potent neutrophil chemoattractants than mCXCL-1 and hCXCL-2, respectively. Both mCXCL-1 and hCXCL-2 are important chemokine signals for recruiting neutrophils to sites of infection. In pulmonary aspergillosis, mCXCL-1 recruits neutrophils into the lung to limit fungal burden (Jhingran et al., 2015) . However, unlike FIGURE 5 hCXCL-2 and hCXCL-2(3-73) prime release of MMP-9 from neutrophils to similar extents. Neutrophils were primed with either medium alone or hCXCL-2 or hCXCL-2(3-73) and then stimulated with medium or 100 nM fMLP as indicated. Approximately 8 μl of diluted supernatant from each condition were run on triplicate 0.2% gelatin SDS-PAGE gels for 1 hr. Digestion of gelatin by MMP-9 was allowed to proceed at 37°C in zymography digestion buffer overnight. Gels were then stained with Coomaisse Blue and de-stained as needed. A representative gel is shown in Figure 5a . Densitometry of each MMP-9 band for each condition was quantified and subtracted from background in Figure 5b . Data represents the mean and SEM of results from three donors. *p < .05, n.s. = not significant pulmonary aspergillosis, blastomycosis is characterized by an overwhelming infiltrate of neutrophils with inefficient clearance of fungal 1, -2, -3, -5, -6, and -7, preferentially bind CXCR2 rather than CXCR1.
Conversely, hCXCL-8 preferentially binds CXCR1 although it can also bind CXCR2 (Ahuja & Murphy, 1996; Baggiolini, Dewald, & Moser, 1997; Geiser et al., 1993) . Nonetheless, stimulating neutrophils with either hCXCL-2 or hCXCL-8 alone can induce a similar suite of functions: an increase in intracellular calcium, neutrophil migration, and ROS production (Magazin et al., 1992) . Because hCXCL-2 likely signals through CXCR2 and hCXCL-8 mainly signals through CXCR1, this suggests that there may be functional overlap between the two receptors.
This point notwithstanding, Jones et al. (Jones, Wolf, Qin, Mackay, & Baggiolini, 1996) reported that mAb against CXCR1 but not CXCR2 blocked ROS production in neutrophils induced by hCXCL-8. This finding would suggest that CXCR1 mediates neutrophil ROS production when ELR + CXC chemokines are the sole stimulus. Although the design of our study is different, for example, the ROS response is primed by ELR + CXC chemokines and stimulated by fMLP, the fact that ROS production may be mediated more efficiently by CXCR1 rather than CXCR2 could explain why hCXCL-2(3-73) does not prime neutrophil ROS production as well as intact hCXCL-2. That is, perhaps the two forms have varied affinity for CXCR1 and CXCR2.
Although hCXCL-2 has a low affinity for CXCR1, it can signal through this receptor (Ahuja & Murphy, 1996; Geiser et al., 1993; Magazin et al., 1992) . We speculate that hCXCL-2(3-73) may have a higher affinity than hCXCL-2 for the CXCR2 receptor, and therefore more hCXCL-2(3-73) binds CXCR2, reducing the amount of hCXCL-2 in Pichia pastoris as described (Sterkel et al., 2016) . Recombinant (r)
hCXCL-1 (Catalog #300-11), -2 (#300-39), and -8 (#200-08 M) and murine (m) CXCL-1 (#250-11) were purchased from Peprotech (Rocky Hill, NJ). Chemokines were resuspended in digestion buffer (40 mM NaCl, 20 mM HEPES, pH 7.4) at a concentration of 40 μg/ml. For rDppIVA digestion of chemokines, 1.5 μg of chemokine was incubated with 300 ng of rDppIVA in 50 μl of buffer. Control reaction lacked rDppIVA to obtain uncleaved chemokine. Reactions were incubated at 37°C overnight and submitted for mass spectrometry analysis the next day. Cuvettes containing 1.5 μg of chemokine without rDppIVA were also incubated at 37°C overnight and submitted for mass spectrometry analysis. To purify cleaved and intact chemokines for in vitro and in vivo assays, samples were loaded onto a 30 K centricon filter (Millepore) and spun at 13,000 × g for 10 min, and the flowthrough containing chemokine was collected. To determine the concentration of filtered hCXCL-2 and hCXCL-2(3-73), a Pierce BCA Protein Assay (Thermo Scientific-23227) was performed following the manufacturer's instructions for a microplate procedure.
| Mass spectrometry
Protein samples were cleaned/concentrated using solid-phase extrac- 
| Mice
Wild-type C57BL/6 mice were purchased from Charles River. Mice used in experiments were 8-to 12-week-old males. Intratracheal (it) and intravenous (iv) treatments were given under anesthesia. All mouse work was in compliance with a protocol approved by the University of Wisconsin IACUC.
| In vivo recruitment by mCXCL-1
To track the effects of cleaved or intact mCXCL-1 (KC), 2 × 10 4 heatinactivated B. dermatitidis yeast (as described by Sterkel et al., 2016) were delivered intratracheally with 100 ng of murine CXCL-1 that had been incubated in digest buffer with or without DppIV as described above. Control mice received PBS vehicle containing heatinactivated yeast. Five hours after intratracheal delivery, mice were euthanized and lungs were harvested and processed for flow cytometry as previously described (Sterkel et al., 2016) . To track the location of neutrophils in the lung, prior to euthanizing mice 2 μg of anti-CD45 (clone 30-F11; BioLegend, San Diego, CA) was injected intravenously to label all leukocytes in the blood (Anderson et al., 2014) .
| Flow cytometry
Enriched neutrophils or lung digest samples were stained and acquired on a LSRII cytometer (BD Biosciences). Data was analyzed using 
| Priming of human neutrophils
For the ROS degranulation assays, and MMP-9 zymography, 1.5-2 × 10 6 purified hPMNs were primed by the addition of modified for 20 min at 37°C with 5% CO 2 .
| Transwell migration assays
Purified hPMNs were resuspended in mHBSS. Calcein AM dye resuspended in DMSO (Sigma-Aldrich D2650) was added to the neutrophils at a final concentration of 3 μM, and cells were incubated in the dark for 20 min to fluorescently label the neutrophils. Labeled hPMNs were pelleted by spinning at 1500 RPM at 25°C for 5 min without accelerator and brake. The supernatant was removed and neutrophils were resuspended in mHBSS. hPMNs were again pelleted without the accelerator and brake. After this, the supernatant was removed and cells were resuspended at 10 6 hPMNs/ml. Two hundred microlitres of the For the medium control, hPMNs were aliquoted to triplicate tubes to be labeled with anti-CD35 or -CD66b antibody and were not treated with fMLP but were incubated at 37°C for 30 min at 5% CO 2 .
| MMP-9 zymography
Approximately 1.9 × 10 6 purified hPMNs were primed for each condition tested. hPMNs were then treated with mHBSS or 1 nM fMLP for 30 min at 37°C with 5% CO 2 . Treated hPMNs were pelleted at 1500 RPM for 5 min without the accelerator and brake. Supernatants were collected and stored at −80°C. Approximately 10% PAGE gels containing 0.2% gelatin were prepared, and 1:8 dilutions of supernatant from each condition were made, mixed with an equal volume of 2X sample buffer (62.5 mM Tris-HCL pH 6.8, 25% glycerol, 4% SDS, 0.01% Bromophenol Blue), and run for 60 min at 200 volts. Gels were incubated in a 2.5% Triton X-100 Buffer for 30 min while shaking at room temperature, at which time the buffer was changed and incubated for another 30 min shaking at room temperature. Gels were next submerged in zymography digestion buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, and 5 mM CaCl 2 ) and incubated at 37°C overnight.
The gels were then incubated with 0.1% Coomassie Blue and imaged on a BioRad Versadoc 5000 (Hercules, CA).
| In vitro neutrophil killing assay
Bone marrow neutrophils were obtained from mice as previously described through Percoll-gradient enrichment (Sterkel et al., 2016) .
Neutrophils were preincubated alone or with 50 ng (final concentration of 250 ng/ml) of mCXCL-1 or mCXCL-1(3-72) for 30 min at 37°C in a 96-well plate. After the priming incubation, DppIVa RNAi yeast (Sterkel et al., 2016) were added to neutrophils to reach an effector-to-target ratio of 50:1. After 6 hr of incubation at 37°C, neutrophils were lysed with water and yeast were spread on brain heart infusion agar plates to innumerate CFU. Percent killing was calculated on the basis of the reduction of CFU compared to control wells lacking neutrophils:
Percent killing ¼ mean control CFU−sample CFU ð Þ = mean control CFU ð Þ ×100%:
4.14 | Effect of mCXCL-1(3-72) and mCXCL-1 on neutrophil function in vivo
Mice were challenged intratracheally with 2 × 10 4 DppIVA RNAi yeast to induce a natural neutrophil response. Two days later, mice received intratracheally 100 ng of mCXCL-1(3-72), mCXCL-1, or PBS alone (vehicle). To quantify fungal burden, 4 hr after chemokine delivery, lungs were harvested and homogenates were spread on brain heart infusion agar plates to quantify CFU. To analyze ROS production of in vivo neutrophils, lungs were harvested just 2 hr after chemokine delivery to limit the effects of additional neutrophil recruitment. Lungs were harvested and processed as noted above. Leukocytes were incubated at 37°C for 4 hr unstimulated with fluorescent ROS probe dihydrorhodamine-123 (DHR-123, Chemodex) at a final concentration of 10 μg/ml in RPMI-1640 with 10% heat-inactivated FBS (Sterkel et al., 2016) . After DHR-123 incubation, leukocytes were washed and stained for flow cytometry as described above. Test was performed to statistically analyze ROS production, CD35
| Graphical and statistical analysis
and CD66b MFI, and zymography densitometry data.
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